Perjeta approved for advanced breast cancer
(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.
HER2 is a protein involved in cell growth. Increased amounts of the protein, which tend to fuel cancer cell growth and survival, are found in about 20 percent of breast cancer cases, the FDA said.
Perjeta was approved for people who haven't been previously treated with an anti-HER2 therapy for metastatic (spreading) breast cancer, the agency said.
But the FDA warned that unspecified "production issues" facing manufacturer Genentech "could affect the long-term supply of the drug." The agency said the drug maker "has committed to take steps designed to resolve these production issues in a timely manner."
The drug's safety and effectiveness were evaluated in a clinical study of 808 people with HER2-positive breast cancer. The most common side effects noted were diarrhea, hair loss, a decrease in white blood cells, nausea, fatigue, rash and nerve damage.
The drug was approved with the agency's "black box" label warning of the potential for death or severe effects to a fetus. A woman's pregnancy status must be verified before she starts treatment with the drug, the FDA said.
San Francisco-based Genentech is a unit of the Roche Group.
More information: The FDA has more about this approval.
Copyright © 2012 HealthDay. All rights reserved.
-
FDA approves Roche skin cancer drug Erivedge
Jan 30, 2012 |
not rated yet |
0
-
Antibody-guided drug shows encouraging activity in metastatic breast cancer
Dec 12, 2009 |
not rated yet |
0
-
HER2 levels may aid in treatment selection for metastatic breast cancer
Dec 02, 2008 |
not rated yet |
0
-
New therapy for HER2-positive breast cancer developed
Jul 26, 2011 |
not rated yet |
0
-
FDA says breast cancer drug did not extend lives
Jul 16, 2010 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
6 hours ago
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Key find for early bladder cancer treatment
Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.
Cancer
47 minutes ago |
5 / 5 (1) |
0
Cold plasma successful against brain cancer cells
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...
Cancer
1 hour ago |
5 / 5 (1) |
0
|
Non-Hodgkin lymphoma survival doubles since early 1970s
More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.
Cancer
1 hour ago |
5 / 5 (1) |
0
Researchers find possible 'master switch' in deadly brain cancer
(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...
Cancer
2 hours ago |
3.5 / 5 (2) |
0
|
American cancer society celebrates 100 years of progress
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer
16 hours ago |
not rated yet |
0
Study reveals active site of enzyme linked to stuttering
(Medical Xpress)—Scientists from the Joint Center for Structural Genomics (JCSG) at SLAC National Accelerator Laboratory have determined the 3-D structure of the chemically active part of an enzyme involved ...
Are kids who take music lessons different from other kids?
(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...
New discovery in fight against deadly meningococcal disease
Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.
Pay attention: How we focus and concentrate
Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.
Parents can help preteens with abduction concerns
Parents naturally are concerned for their children's safety, particularly when there is news of a child abduction that happens close to home. Finding the balance between emotions and the "teachable moment" as parents talk ...
New imaging techniques used to help patients suffering from epilepsy
New techniques in imaging of brain activity developed by Jean Gotman, from McGill University's Montreal Neurological Institute, and his colleagues lead to improved treatment of patients suffering from epilepsy. The combination ...
